CNTX Stock Summary and Trading Ideas (Context Therapeutics | NASDAQ:CNTX)

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Context Therapeutics trades on the NASDAQ stock market under the symbol CNTX.

As of April 2, 2026, CNTX stock price climbed to $2.72 with 969,560 million shares trading.

CNTX has a beta of 0.78, meaning it tends to be less sensitive to market movements. CNTX has a correlation of 0.02 to the broad based SPY ETF.

CNTX has a market cap of $249.91 million. This is considered a Small Cap stock.

Last quarter Context Therapeutics reported $0 in Revenue and -$.14 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.03.

In the last 3 years, CNTX traded as high as $3.62 and as low as $.47.

The top ETF exchange traded funds that CNTX belongs to (by Net Assets): VTI, VXF, AVSC.

CNTX has outperformed the market in the last year with a return of +299.4%, while the SPY ETF gained +17.5%. In the last 3 month period, CNTX beat the market returning +75.5%, while SPY returned -3.7%. However, in the most recent 2 weeks CNTX has underperformed the stock market by returning -9.0%, while SPY returned -0.1%.

CNTX support price is $2.46 and resistance is $2.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNTX shares will trade within this expected range on the day.